Multiple Microvascular Alterations in Pancreatic Islets and Neuroendocrine Tumors of a Men1 Mouse Model

被引:25
|
作者
Chu, Xia [1 ]
Gao, Xiang [2 ]
Jansson, Leif [2 ]
Quach, My [2 ]
Skogseid, Britt [1 ]
Barbu, Andreea [1 ]
机构
[1] Uppsala Univ, Dept Med Sci, S-75185 Uppsala, Sweden
[2] Uppsala Univ, Dept Cell Biol, S-75185 Uppsala, Sweden
来源
AMERICAN JOURNAL OF PATHOLOGY | 2013年 / 182卷 / 06期
基金
瑞典研究理事会;
关键词
FIBROBLAST-GROWTH-FACTOR; ENDOCRINE NEOPLASIA TYPE-1; BLOOD-FLOW; NITRIC-OXIDE; IN-VIVO; MICROVESSEL DENSITY; ENDOTHELIAL-CELLS; FACTOR EXPRESSION; PDGF-B; ANGIOGENESIS;
D O I
10.1016/j.ajpath.2013.02.023
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Vascular therapeutic targeting requires thorough evaluation of the mechanisms activated in the specific context of each particular tumor type. We highlight structural, molecular, and functional microvascular aberrations contributing to development and maintenance of pancreatic neuroendocrine tumors (NETs), with special reference to multiple endocrine neoplasia 1 (MEN1) syndrome, using a Men1 mouse model. Tissue samples were analyzed by immunofluorescence to detect vessel density and pericyte distribution within the endocrine pancreas; expression of angiogenic factors was assessed by immunohistochemistry and quantitative real-time PCR in isolated islets and adenomas cultured under normoxic or hypoxic conditions. The increased vascular density of pancreatic NETs developed in Men1 mice was paralleled by an early and extensive redistribution of pericytes within endocrine tissue. These morphological alterations are supported by, and in some cases preceded by, fine-tuned variations in expression of several angiogenic regulators and are further potentiated by hypoxia. By combining two novel ex vivo and in vivo single-islet and tumor perfusion techniques, we demonstrated that both vascular reactivity and blood perfusion of tumor arterioles are significantly altered in response to glucose and L-nitro-arginine methyl ester. Our findings unravel multiple potential molecular and physiological targets differentially activated in the endocrine pancreas of Men1 mice and highlight the need for in-depth functional studies to fully understand the contribution of each component to development of pancreatic NETs in MEN1 syndrome.
引用
收藏
页码:2355 / 2367
页数:13
相关论文
共 50 条
  • [21] DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors
    Jiao, Yuchen
    Shi, Chanjuan
    Edil, Barish H.
    de Wilde, Roeland F.
    Klimstra, David S.
    Maitra, Anirban
    Schulick, Richard D.
    Tang, Laura H.
    Wolfgang, Christopher L.
    Choti, Michael A.
    Velculescu, Victor E.
    Diaz, Luis A., Jr.
    Vogelstein, Bert
    Kinzler, Kenneth W.
    Hruban, Ralph H.
    Papadopoulos, Nickolas
    SCIENCE, 2011, 331 (6021) : 1199 - 1203
  • [22] Prognostic factors for the outcome of nonfunctioning pancreatic neuroendocrine tumors in MEN1: a systematic review of literature
    Sadowski, S. M.
    Pieterman, C. R. C.
    Perrier, N. D.
    Triponez, F.
    Valk, G. D.
    ENDOCRINE-RELATED CANCER, 2020, 27 (06) : R145 - R161
  • [23] Pancreatic neuroendocrine tumors in MEN1 disease: a mono-centric longitudinal and prognostic study
    S. Chiloiro
    F. Lanza
    A. Bianchi
    G. Schinzari
    M. G. Brizi
    A. Giampietro
    V. Rufini
    F. Inzani
    A. Giordano
    G. Rindi
    A. Pontecorvi
    L. De Marinis
    Endocrine, 2018, 60 : 362 - 367
  • [24] MEN1 promotes ferroptosis by inhibiting mTOR-SCD1 axis in pancreatic neuroendocrine tumors
    Ye, Zeng
    Chen, Haidi
    Ji, Shunrong
    Hu, Yuheng
    Lou, Xin
    Zhang, Wuhu
    Jing, Desheng
    Fan, Guixiong
    Zhang, Yue
    Chen, Xuemin
    Zhuo, Qifeng
    Chen, Jie
    Xu, Xiaowu
    Yu, Xianjun
    Xu, Jin
    Qin, Yi
    Gao, Heli
    ACTA BIOCHIMICA ET BIOPHYSICA SINICA, 2022, 54 (11) : 1599 - 1609
  • [25] Higher Risk of Aggressive Pancreatic Neuroendocrine Tumors in MEN1 Patients With MEN1 Mutations Affecting the CHES1 Interacting MENIN Domain
    Bartsch, Detlef K.
    Slater, Emily P.
    Albers, Max
    Knoop, Richard
    Chaloupka, Brunhilde
    Lopez, Caroline L.
    Fendrich, Volker
    Kann, Peter H.
    Waldmann, Jens
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2014, 99 (11): : E2387 - E2391
  • [26] Utility of FDG-PET Imaging for Risk Stratification of Pancreatic Neuroendocrine Tumors in MEN1
    Jackson, Elena R. Kornaczewski
    Pointon, Owen P.
    Bohmer, Robert
    Burgess, John R.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2017, 102 (06): : 1926 - 1933
  • [27] Update on the role of the robotic assisted surgery in the treatment of pancreatic neuroendocrine tumors in the context of MEN1
    Yiannakopoulou, E.
    JOURNAL OF NEUROENDOCRINOLOGY, 2021, 33 : 221 - 221
  • [28] The Management of Neuroendocrine Tumors of the Lung in MEN1: Results From the Dutch MEN1 Study Group
    van den Broek, Medard F. M.
    de Laat, Joanne M.
    van Leeuwaarde, Rachel S.
    van de Ven, Annenienke C.
    de Herder, Wouter W.
    Dekkers, Olaf M.
    Drent, Madeleine L.
    Kerstens, Michiel N.
    Bisschop, Peter H.
    Havekes, Bas
    Hackeng, Wenzel M.
    Brosens, Lodewijk A. A.
    Vriens, Menno R.
    Buikhuisen, Wieneke A.
    Valk, Gerlof D.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2021, 106 (02): : E1014 - E1027
  • [29] Duodeno Pancreatic Neuroendocrine Tumors (DPNET) in Multiple Endocrine Neoplasia Type 1 (MEN1): An Italian Restrospective, Observational, Multicenter Study
    Modica, R.
    Davi, M., V
    Brighi, N.
    Massironi, S.
    Pusceddu, S.
    Zatelli, M. C.
    Albertelli, M.
    Malandrino, P.
    De Luca, I
    Grimaldi, F.
    Colao, A.
    Faggiano, A.
    NEUROENDOCRINOLOGY, 2019, 108 : 82 - 82
  • [30] Diagnostic and Clinical Management of Pancreatic Neuroendocrine in MEN1 Syndrome
    Chiloiro, S.
    Epifani, V
    Bianchi, A.
    Giampietro, A.
    Piacentini, S.
    Bima, C.
    Rufini, V
    Brizi, M. G.
    Giordano, A.
    Rindi, G.
    Pontecorvi, A.
    De Marinis, L.
    NEUROENDOCRINOLOGY, 2018, 106 : 67 - 67